4 ms·
The antibody-dependent enhancement problem is mentioned in the article, but I think it needs a longer explanation. From https://en.wikipedia.org/wiki/Antibody-d
by gus_massa 6y ago
The antibody-dependent enhancement problem is mentioned in the article, but I think it needs a longer explanation. From https://en.wikipedia.org/wiki/Antibody-dependent_enhancement https://en.wikipedia.org/wiki/Antibody-dependent_enhancement
> Antibody-dependent enhancement (ADE), sometimes less precisely called immune enhancement or disease enhancement, is a phenomenon in which binding of a virus to suboptimal antibodies enhances its entry into host cells, and sometimes also its replication.[1] This phenomenon—which leads to both increased infectivity and virulence—has been observed with mosquito-borne flaviviruses such as Dengue virus, Yellow fever virus and Zika virus,[2][3] with HIV, and with coronaviruses.[4]
where [4] is https://www.ft.com/content/f1b25b41-f3cf-4a73-ba8f-582385bc2eeb https://www.ft.com/content/f1b25b41-f3cf-4a73-ba8f-582385bc2... that says about SARS (2003):
> Some animals that were given experimental Sars vaccines suffered more severe lung inflammation than unvaccinated animals when subsequently infected. Those trials stopped and there is still no effective Sars vaccine.
- robocat 6y agoFrom confiks answer: They argue that antibody-dependent enhancement (ADE) specifically is less likely because the immune response of the intranasal vaccine is limited to the mucosal tissue [2]. [1] https://radvac.org/wp-content/uploads/2020/07/White-Paper-SA.. https://radvac.org/wp-content/uploads/2020/07/White-Paper-SA.... [2] See [1] page 6